Skip to content
Review

Mechanistic Evaluation of Psilocybin in Neurodegenerative Disorders: Relevance of 5-HT2A Receptors and Downstream Pathways.

Oct 2026 · CNS and Neurological Disorders - Drug Targets · Vol 25 · 0 citations
Medicine

TL;DR

This review incorporates the most recent data on psilocybin's chemistry, pharmacology, metabolism, and mechanistic actions and highlights the drug's therapeutic potential across a variety of neurodegenerative diseases and emphasizes the necessity of carefully planned randomized controlled trials to determine clinical efficacy, long-term safety, and its place in multimodal treatment approaches.

Abstract

More than fifty million individuals worldwide are experiencing neurodegenerative disorders, which include Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and frontotemporal dementia. These disorders have a significant role in the gradual degradation of cognition and motor skills. Most current treatment approaches have little effect on changing the course of the disease and are largely symptomatic. Psilocybin, a naturally occurring tryptamine alkaloid from psilocybin mushrooms, has become a promising medicinal agent because of its hallucinogenic, neuroprotective, and neuroplastic properties. After being metabolically transformed into its active form, psilocin, it primarily activates serotonin 5-HT2A receptors. This modulates glutamatergic neurotransmission and neurotrophic signaling pathways such as BDNF/TrkB and mTOR, which regulate synaptic remodeling, dendritic complexity, neurogenesis, neuroinflammatory response, and default mode network connectivity, all of which are linked to depression and dementia. Preclinical research studies demonstrate that psilocybin increases hippocampal plasticity, restores dendritic complexity, lowers proinflammatory cytokine levels, and promotes fear extinction in experimental models of stress, ischemic stroke, and neurodegeneration. Emerging clinical studies also indicate that individuals with moderate cognitive impairment, early-onset Alzheimer's disease, and Parkinson's disease may see long-term decreases in anxiety and depression as well as improvements in cognitive function, frequently after a single dose administration. Additionally, psilocybin has demonstrated promise in treating mental comorbidities that often accompany neurodegenerative illness, such as treatment-resistant depression, drug use disorders, and obsessive-compulsive disorder. However, there are still significant obstacles to overcome, such as optimizing dosing schedules, assessing safety issues such as temporary perceptual abnormalities and cardiovascular consequences, and translating preclinical results into extensive phase -III clinical studies. This review incorporates the most recent data on psilocybin's chemistry, pharmacology, metabolism, and mechanistic actions; it highlights the drug's therapeutic potential across a variety of neurodegenerative diseases and emphasizes the necessity of carefully planned randomized controlled trials to determine clinical efficacy, long-term safety, and its place in multimodal treatment approaches.

View source

Similar papers

Review Open access Oct 2026

Recent advances of GPR40 agonists as potential anti-Alzheimer's agents.

Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disorder involving metabolic dysfunction, neuroinflammation, mitochondrial impairment, synaptic failure, and neuronal loss. Although amyloid-beta deposition and neurofibrillary tangles composed of hyperphosphorylated tau remain central patho...

Jefferson Muniz Alves da Silva, A. Kümmerle, D. A. Rodrigues et al. · 0 citations
Review Oct 2026

Dual targeting of melatonergic and serotonergic neurotransmissions in Parkinson's disease: role of agomelatine.

Parkinson's disease (PD) is a progressive neurodegenerative disorder of the central nervous system (CNS), driven by the pathological aggregation and accumulation of α-synuclein (α-Syn) within dopaminergic neurons of the substantia nigra pars compacta (SNpc). Despite extensive research, the pathogenesis of PD remains in...

Hayder M. Al-kuraishy, M. Naji, R. R. Abd Hasan et al. · 0 citations
Review Open access Oct 2026

Molecular Mechanistic Insights into Selected Phytochemicals for the Management of Alzheimer’s Disease

Alzheimer's disease (AD) is a progressive neurodegenerative disease, which is marked by mental loss, impaired memory, and behavioural abnormalities, and is one of the causes of dementia in the world. Extracellular plaques of amyloid-beta, intracellular neurofibrillary tangles, cholinergic dysfunction, oxidative stress,...

Deepa P, N. Varghese · 0 citations
Review Open access Sep 2026

The Role of Curcumin in Neurogenesis and Neuroprotection in Alzheimer’s disease: From Molecular Mechanisms to Clinical Evidence

This review discusses multi-target neuroprotective mechanisms of curcumin, critically reviews the preclinical success and human clinical trial outcomes, and highlights advanced nano formulations (solid lipid nanoparticles, colloidal sub-micron dispersions, polymeric nanoparticles, multi-walled carbon nanotubes and exos...

V. S, Sarupruthiya M, Jeevitha D et al. · 0 citations
Review Open access Oct 2026

Repurposing Retatrutide for Neuroprotection in Parkinson’s Disease: A Comprehensive Review

Parkinson's disease is a progressive neurodegenerative condition marked by the loss of dopaminergic neurons, mitochondrial dysfunction, oxidative stress, and persistent neuroinflammation. Recent findings suggest that impaired glucose metabolism and disrupted energy balance may play a role in the early stages of the dis...

Sivakumar G., T. K, N. K. et al. · 0 citations
Review Oct 2026

Cannabidiol in Alzheimer’s disease: evidence-weighted molecular mechanisms and translational challenges

Current preclinical evidence supports continued investigation of CBD as a multi-target neuroprotective candidate in AD, provided that future studies use standardized, mechanism-focused and translationally relevant designs.

Sreenivasulu Sura, S. Jagadeesan, S. S. Masrudin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.